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Tumors must evade the immune system to survive and metastasize, although the mech-
anisms that lead to tumor immunoediting and their evasion of immune surveillance are
far from clear. The first line of defense against metastatic invasion is the innate immune
system that provides immediate defense through humoral immunity and cell-mediated
components, mast cells, neutrophils, macrophages, and other myeloid-derived cells that
protect the organism against foreign invaders. Therefore, tumors must employ different
strategies to evade such immune responses or to modulate their environment, and they
must do so prior metastasizing. Exosomes and other secreted vesicles can be used for
cell–cell communication during tumor progression by promoting the horizontal transfer of
information. In this review, we will analyze the role of such extracellular vesicles during
tumor progression, summarizing the role of secreted vesicles in the crosstalk between
the tumor and the innate immune system.
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INTRODUCTION
Cancer is a systemic disease that has mostly been studied by
focusing on the primary tumor. Hence, there is little information
available as to how the tumor microenvironment influences tumor
progression and metastasis. To date, whether a tumor influences its
microenvironment or conversely, whether an aberrant microenvi-
ronment reinforces tumor progression, is a fundamental question
in tumor biology. Metastatic cells conquer new organs after a phe-
notypic evolution that not only allows them to move from the
primary tumor but also to evade innate and adaptive immune
responses. Innate immunity protects us against pathogens or
potential invaders. However, it is not clear how the innate immune
system acts during tumor progression and metastasis. Among the
most important questions that remain to be resolved are whether
innate immune cells are present during tumor progression and metas-
tasis and if so, which are their roles?, Is the microenvironment
involved in the failure of current therapies and if this is the case,
can we “educate” our immune system to control or impede metas-
tasis? In this review, we will focus on how cancer cells interact
with the innate immune system during metastasis, highlighting
the potential role of secreted vesicles in this process.
INNATE IMMUNITY IN METASTASIS, THE FIRST LINE OF
DEFENSE
There are different factors that can promote tumor progression
and eventually metastasis, such as unbalanced growth signaling,
alterations to the cell cycle, genomic mutations, and immune
evasion. Metastasis is a complex event that accounts for more
than 90% of cancer-related deaths, and it reflects the evolution
of the primary tumor through its interaction with the microen-
vironment of local and distant organs (1, 2). Tumor cells migrate
from primary tissues by degrading the surrounding tissue and
extracellular matrix, spreading through the blood or lymphatic
vessels before reaching their newfound land (3). Lyden and col-
leagues defined the novel concept of “premetastatic niche” in which
stromal cells such as bone marrow-derived cells, under the spell
of the primary tumor, are actively involved in the formation of a
suitable microenvironment for the metastasis to develop at dis-
tant sites (4). Therefore, cancer cells not only need to promote
their own immortality and invade propitious territories but they
also need to evolve along with the microenvironment and to find
strategies that enable them to survive from the constant immune
surveillance (5).
Tumors use two major strategies to escape from immune sur-
veillance: immunoediting, in which the least immunogenic tumor
cell variants are selected; and active suppression of the immune
response along with establishing conditions, within the tumor
microenvironment, that facilitate tumor outgrowth (6). Innate
and adaptive immunity and their responses must be overcome
by tumors in order to evade their effects (7). Escaping from innate
immunity, the first barrier of defense against microbial molecules
may be one of the earliest events in the progression of the local
tumor into a metastatic cancer. However, cancer immunoediting
involves the use of the immune system’s host-protective events
to promote tumor progression and the escape of cancer cells from
immune responses, allowing them to develop immune evasive fea-
tures (8). Indeed, both innate and adaptive immunity appear to
contribute to cancer immunoediting (9).
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THE INNATE IMMUNE RESPONSE CONTROLS THE BALANCE
BETWEEN THE HOST AND TUMOR MICROENVIRONMENT
Tumor development and metastasis are influenced by the stroma,
by angiogenesis, and by the innate and adaptive immune system.
The concept of tumor immune surveillance was first contem-
plated by Paul Ehrlich in 1909, postulating that the immune
system can restrict the spontaneous growth of transformed cells
by identifying and eliminating them (10). About 50 years later,
Burnet and Thomas proposed that tumor-associated antigens
can provoke an effective immunological reaction (11). This ini-
tial theory of immune surveillance was controversial, especially
given the evidence that nude mice that lack an intact immune
system are not more susceptible to tumor development (12). In
2001, it was shown that lymphocytes and IFNγ collaborate to
prevent tumor immunoediting, thereby preventing the selection
of less immunogenic tumor cells (13). Natural killer (NK) cells
are the immune effector cells that are active in the elimination
of transformed cells but that also promote the maturation and
migration of dendritic cells (DCs) with enhanced antigen presen-
tation to T cells (14). In cancer, NK cell activity and the ability
to infiltrate tumors may be impaired, and for example, chronic
exposure to NK group 2 D (NKG2D) ligand-expressing tumor
cells alters NKG2D function in NK cells, promoting NK cell eva-
sion by tumor cells (15). Although the activation of immune
cells could result in the eradication of transformed cells, chronic
activation of innate immunity, like chronic inflammation, might
promote cancer development (16). Cancer has been compared
to a wound that never heals (17), based on the observation that
the tumor is in a state of chronic inflammation. Indeed, immune
cells, such as macrophages and mast cells, release soluble agents
like cytokines and chemokines promoting the migration and infil-
tration of leukocytes that can contribute to tumor growth (18).
Thus, better understanding how innate tumor surveillance occurs
could guide tumor immune therapy that would potentiate the
immune system to act against cancer through immunomodulatory
approaches.
EXTRACELLULAR VESICLES AND INNATE IMMUNITY: A
FIRST CONTACT
Most cell types secrete vesicles, and there are many different
vesicle types that fulfill a wide range of biological functions.
Although the nomenclature is still not fully accepted, one can
classify them based on their secretory pathway, and these vesi-
cles can be divided into membrane-derived vesicles and exosomes
(19, 20). The term exosome was initially used to name vesicles
ranging from 40 to 1000 nm in size that are released by a variety
of cultured cells that were defined as “exfoliated membrane vesi-
cles that may serve a physiological function” (21). However, this
term was later adopted for smaller (30–100 nm) vesicles of endo-
somal origin that are released as a consequence of the fusion
of multivesicular bodies with the plasma membrane, enriched
of specific markers such as CD63, CD81, and CD9 (Figure 1)
(20, 22). Ectosomes, also called shedding vesicles, microparti-
cles, or microvesicles, are variable in size (0.1–1µm), origin and
cargo. Their secretion occurs through budding from the plasma
membrane. Ectosomes are secreted by many cell types including
platelets, endothelial cells, and leukocytes, and they are released
FIGURE 1 | Biological function of exosomes. Exosomes are small
vesicles (30–100 nm) generated in the endosomal structure and released
from several cellular types. They are considered fundamental for cell–cell
information exchange, and they contain specific cargo such as DNA, RNA,
miRNA, and proteins. Biological functions of exosomes include antigen
presentation, regulation of programmed cell death, angiogenesis,
inflammation, and coagulation. Exosomes are enriched of specific markers
such as CD63, CD81, and CD9.
directly into the blood (23). Extracellular vesicles were thought
to discard cellular debris from cells; yet during the last decade,
they have been shown to play an active role in cell communication
and, in particular, cell–cell communication. They carry molecular
determinants of their cell or tissue of origin including DNA, RNA,
miRNA, proteins, lipids, and other cargo (Figure 1) (20). The
biological functions of exosomes include antigen presentation,
regulation of programmed cell death, angiogenesis, inflammation,
and coagulation (24). Most studies of exosomes have been carried
out in relation to immune or cancer cells (25), as well as study-
ing the potential effects of tumor-derived exosomes in modulating
immune interactions. The mechanisms that guide tumor cells to
a specific tissue are largely unknown, although there is evidence
that tumor cells themselves modulate immune cells and tissues
through the secretion of soluble factors and vesicles (2, 26, 27).
Exosomes may be vehicles for many different activities exerted
over target cells (20). Indeed, we recently showed that melanoma-
secreted exosomes transfer information and reprogram bone mar-
row progenitor cells toward a pro-vasculogenic phenotype in the
premetastatic niche, acting through the receptor tyrosine kinase,
MET (28). However, the effects of exosome-enriched proteins on
immune cells and, in particular, their effects on tumors and innate
immunity are not fully understood (29). Although the innate
response involves many cell types, it is particularly dependent
on basophils and mast cells (inflammation), and on neutrophils
and macrophages (phagocytosis). There are evidence of secreted
vesicles in most of the innate immunity cellular components.
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Accordingly, here we shall address the possible involvement of exo-
somes in modulating the activity of different elements involved in
innate immunity.
MAST CELLS
As well as fulfilling a key role in allergy, mast cells also have other
immunomodulatory functions, both pro-inflammatory and anti-
inflammatory (30). The pro-inflammatory role of mast cells has
been demonstrated to support the tumor microenvironment in
different cancer models with different chemokines and cytokines
determining the interplay of mast cells with other members of the
immune system (31). Stem cell factor (SCF) is a decisive factor in
the differentiation, maintenance, and activation of mast cells (32).
Indeed, SCF recruits mast cells, and its expression in experimental
models of breast and hepatocarcinoma (33). Mast cells are derived
from myeloid progenitor cells in the bone marrow, and then
undergo differentiation at peripheral sites, where they become spe-
cialized into various subtypes (34). Their location allows them to
interact with different insults and external threats, so they could
be considered as the first line of the immune defense (35). The
levels of some proteases present in mast cells are related to tumor
progression. Mast cells release proteins that have been correlated
with microvessels density, tumor progression, and angiogenesis
such as histamine, which could increase new vessels permeabil-
ity, promoting leakiness (36, 37). Similarly, MMP-2 and MMP-9
stored in mast cell granules, or the secretion of FGF-2,VEGF, TGF-
β, or TNF-α could be involved promoting angiogenesis (38). Mast
cells have been reported to release exosomes that contain differ-
ent proteins, providing an additional mechanism of intercellular
communication (39–41). The content of these vesicles has been
analyzed in detail and the mast cell exosome-derived cargo identi-
fied. Mast cell-derived exosomes contain immunologically deter-
minant factors such as MHC class II proteins (42), co-stimulatory
(CD86, CD40, CD40L), and adhesion-related (LFA-1, ICAM-1)
molecules (40) (Figure 2). They also include CD13, ribosomal
protein S6 kinase, annexin V, cdc25, and phospholipases, together
with other interacting proteins like aldolase A and heat shock pro-
tein 70 (43). The receptor Fcε-RI subunits alpha and beta have
been detected in exosomes (44), contributing to the idea that
secreted vesicles could amplify immune modulation (Figure 3).
Bone marrow-derived mast cells can induce resting B cells to
proliferate and to produce IgM (45). What was thought to be a
non-contact mechanism was described later as exosome-mediated
interaction. These mast cell-derived exosomes are responsible of
inducing B-cell production of IL-2, IL-12, INF-γ, IgG1, and IgG2,
but not IL-4 (40). Functional mRNAs and small RNAs, including
microRNAs have also been found in mast cell-derived exosomes
(Figure 2) (41, 46). The RNA contained in the mast cell-derived
exosomes was first described by Lötvall and Valadi as exosomal
shuttle RNA (esRNA), being functional and transferring informa-
tion between cells (47). The evidence suggest a role for exosomes
in transferring relevant information between stromal and tumor
cells (28), exhibiting new potential communication mechanisms
(Figure 3).
Although the role of mast cells in cancer has been studied
widely, this issue is still not yet fully understood. An increase in
the mast cell population is associated with poor prognosis in many
different cancers, including oral squamous carcinoma, Hodgkin’s
lymphoma, diffuse large B-cell lymphoma, and prostate cancer
(48–52). A positive correlation was described in prostate cancer,
colon, and breast cancer (53). The location of mast cells might
be an essential factor in their role in tumor rejection or pro-
gression. In non-small cell carcinoma, intra-tumoral detection is
associated with improved survival (54). In melanoma, mast cell
accumulation in the margins of the tumor has been observed
(55). c-Kit and Fcε-R1, phenotypical markers for mast cells, are
involved in tumor progression and exosomal communication.
Interestingly, c-Kit-containing exosomes have been described as
a mechanism for progression in lung adenocarcinoma enhanc-
ing tumor cell proliferation (56). These data, together with our
FIGURE 2 | Innate immune cells and their extracellular vesicles. The
innate immunity is the first barrier of defense against infection and tumoral
invasion. It includes humoral factors and many cellular types such as mast
cells, neutrophils, macrophages, and NK cells. It is reported that several
cellular components of the innate immunity secrete vesicles modulating
the direction of the immune response.
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FIGURE 3 |Vesicle-mediated interactions between tumor and innate
immunity. In this microenvironment–tumor interaction model, tumors
secrete exosomes that are responsible for the recruitment of neutrophils and
eosinophils, proliferation of NK cells, and activation of macrophages
promoting their polarization. When recruited, eosinophils can release their
granules having a role in cytotoxic response and immune surveillance. The
neutrophils can release vesicles during inflammation activated-process and
could have a role in cancer-related inflammation and tissue remodeling. The
macrophage-secreted exosomes may regulate the tumor invasiveness and
the metastatic behavior; however, specific cargo has not yet been described,
while exosomes derived from NK cells may exert a role in immune cytoxicity.
Mast cell exosome-derived cargo is described to contain functional mRNAs
and small RNAs, immunological proteins and could be involved in
immunomodulation, B-cell activation and inflammation.
recently published data about the influence of c-MET secreted
on tumor-derived exosomes to bone marrow progenitor cells
during melanoma metastatic progression (28), suggest that hori-
zontal transfer of oncoproteins between tumor and bone marrow-
derived cells by exosomes play central role in tumor progression.
However, the actions of these exosomal proteins in the environ-
ment and their role in establishing either a premetastatic niche
or promoting tumor growth are yet to be revealed. Secretion of
exosomes is a novel mechanism that expands their role far beyond
their already known role in allergy. Increasing body of evidence
suggest that mast cell-derived exosomes as potential “modula-
tors” of the crosstalk between immune cells and stromal cells.
Mast cell-secreted exosomes may have a double-edged function,
while they can act through stimulating the immune system during
the early events of cancer or when in contact with foreign sub-
stances, they could also be involved in the tumorigenic progression
by the recruitment of macrophages, fibroblasts, and blood ves-
sels that contribute to tumor growth by secreting a milieu of
molecules.
NEUTROPHILS
Neutrophils are key mediators of the innate immune system, and
their activation is essential to protect the host system against
infections and to promote healing (57). The short life span of neu-
trophils and their specific differentiated phenotype has masked
their role in cancer-related inflammation, which is why they
have been largely ignored. Similar to macrophages, the so-called
tumor-associated neutrophils (TAN) can exert pro-tumoral as
well as anti-tumoral effects. Evidence from animal models sug-
gests that neutrophils can be polarized toward distinct phenotypes
in response to different tumor-derived signals (58). The role of
neutrophils in tumor progression is not fully understood. They
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gather in metastatic carcinomas modifying the tumor microen-
vironment by secreting factors like G-SCF or MMP-9 among
others (59, 60), and promoting therefore angiogenesis and vas-
cular remodeling. Tumor exosomes act promoting tumor growth
through bone marrow progenitor cells education and through
neutrophils recruitment (61). Macrophages and DCs are capable
of secreting LTB4-producing exosomes (62), which may induce
neutrophils recruitment. This calling effect is performed in a
gradual fashion that might act like an exosomal gradient (63).
Cytokines and secreted factors stored in neutrophils granules may
play a role in tumor progression (Figure 3). Epithelial lung cancer
cells uptake neutrophil elastase (NE) and favor tumor cell pro-
liferation through the hydrolysis of IRS-1 (64). The acquisition
of NE by cancer cells confers them a previously unknown mech-
anism of anti-tumor adaptive immunity (65). Fridlender et al.
have demonstrated that TGF-β drives neutrophils to acquire a
pro-tumorigenic N2-phenotype, whereas its inhibition enhances
the emergence of an anti-tumorigenic N1-phenotype, character-
ized by cytotoxic activity on cancer cells and an immunostim-
ulatory profile (i.e., high levels of TNF-α, CCL3, and ICAM-1)
(58). Human neutrophils release microvesicles with antibacter-
ial properties, and their cargo, in terms of antimicrobial pro-
teins (Figure 2), is different in the depending on the stimuli
(66). When activated in vitro and in vivo, in local and sys-
temic inflammation, neutrophil microvesicles are shed through
an exocytotic process and they have been denominated ecto-
somes (Figure 2) (67). These vesicles contain cytosolic F-actin
indicating their outside-out orientation, but their content and
unique characteristics suggest a role in inflammation (68). Ecto-
somes activate multiple signaling pathways in neutrophils and
macrophages, leading to TGFβ1 secretion, and may play a role
in macrophage and TAN polarization (69). Neutrophil-derived
ectosomes contain TGF-β, MMP-9, myeloperoxidase, proteinase
3, or elastase (Figures 2 and 3), postulating them as candi-
dates for determinant roles in inflammation and cancer sig-
naling (Figure 3) (70). While the classical role of neutrophils
and their secreted vesicles has been described as antibacterial
agents, recent data suggest that they could also play a role in
inflammation and influence tumor immunosurveillance. Secre-
tion of molecules such as proteases and elastases would impact
in the ECM remodeling necessary for tumor progression, recruit-
ment of neutrophils, and release of their exosome cargo to the
tumor microenvironment could therefore be involved not only
in primary tumor progression but also in the formation of
metastatic foci.
MACROPHAGES
Macrophages are closely involved in the inflammatory responses
observed during cancer and metastasis (Figure 2). Many obser-
vations indicate that tumor-associated macrophages (TAM) have
several pro-tumoral functions, including the expression of growth
factors and MMPs, the promotion of angiogenesis, and the sup-
pression of adaptive immunity (16). Tumor-secreted exosomes
promote the activation of macrophages, as evident by NF-κB activ-
ity (71). Cancer cells secrete factors that modulate macrophage
activation and polarizations into M2 macrophages (Figure 3).
However, the mechanisms that mediate such polarizations are not
clear. Glycoprotein MFG-E8 is associated with the suppression
of pro-inflammatory responses, and it is more concentrated in
exosomes from the tissue and serum of prostate cancer patients
(72). Indeed, the administration of an antibody against MFG-E8
significantly attenuates M2 polarization (72). Therefore, one of
the potential roles of tumor-derived exosomes, in this context,
would be the regulation of M1/M2 polarization. The contribution
of exosomal miR-233 in autocrine differentiation of macrophages
has also been proposed (Figure 3) (73). Macrophages infected
with intracellular pathogens such as Mycobacterium tuberculo-
sis, Mycobacterium bovis BCG, Salmonella typhimurium, or Toxo-
plasma gondii release exosomes that contain pathogen-associated
molecular patterns (PAMPs). These exosomes have immunomod-
ulatory properties over naïve macrophages and neutrophils both
in vitro and in vivo (74). Amoeboid prostate cancer cells have
also been described to secrete miR-125a, which suppresses AKT1
expression and hence, the proliferation in recipient human periph-
eral blood mononuclear cells and macrophages (75). It was
recently described that breast cancer-derived exosomes are capable
of inducing an inflammatory response in macrophages through
NF-κB activation, as seen in other pathologies (76), and that this
may contribute to metastasis (77). Tumors may use exosome-
mediated macrophage polarization to reinforce the escape of
tumors from immune surveillance and in this sense, macrophage-
derived exosomes regulate integrin β1 expression in endothelial
cells in vitro, eventually promoting endothelial migration (78). Its
contribution to vascular leakiness and tumor invasion is plausi-
ble but not determined yet. Macrophage-secreted exosomes may
regulate the invasiveness of breast cancer cells through the deliv-
ery of oncogenic miRNAs. For example, miR-223 was detected
within the exosomes promoting the invasion of breast cancer cells
via the Mef2c-β-catenin pathway (73). These data suggest that
exosome communication and transfer of information between
tumor cells and macrophages could be actively involved in regu-
lating tumor progression (Figure 3) (79). Although macrophage-
secreted exososomes could play an active role regulating phago-
cytic events and degradation of foreign substances, there are a
reduced number of evidence of their physiological function. How-
ever, their role in cancer is better defined, the continuous stimula-
tion by the primary tumor normally overcome the macrophage-
driven immunosurveillance. One potential consequence of the
massive secretion of exosomes by macrophages in pathological
scenarios would be the generation of an inflammatory microenvi-
ronment, which may ultimately result in an enhanced metastatic
burden.
EOSINOPHILS
Eosinophils are traditionally considered to be effector cells in
allergic diseases and infections due to their cytotoxic potential
(Figure 2). They are involved in the inflammatory response due
to the production and release of a wide set of cytokines and medi-
ators (80). Their granules contain highly cytotoxic proteins, such
as major basic protein (MBP) or eosinophil peroxidase (EPO)
(Figure 2), and they can present antigens, release other inflamma-
tory mediators and participate in the regulation of the adaptive
immune response. Like members of the innate immune system,
eosinophils have been observed in the tumor-infiltrating area, and
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their presence is correlated with good prognosis, irrespective of
other prognostic factors such as stage, age, and histological grading
(81). It is not fully understood what mechanisms drive eosinophil
recruitment to the tumor site (82), although some tumor cells
secrete IL-5 and IL-3 that modulate the differentiation and mat-
uration of eosinophils and mast cells (83). A variety of studies
indicate that eosinophils might be more than just an effector of
tumor surveillance, indicating that they are capable of process-
ing insults and of orchestrating a quick and selective response,
mediated through the release of their contents (84).
Eosinophilic granules have been described intensely, and some
of their features are similar to those features of exosomes (Figure 2)
(85). Specific granules of human eosinophils are notable for
their storage role for various proteins, such as EPO, MBP, and
eosinophil-derived neurotoxin (Figure 3), all of them with potent
cationic properties. In addition, these granules contain cytokines,
chemokines, and growth factors, including IL-2, -3, -4, -5, -6,
-10, -12, and -13, IFN-γ, TNF-α, NGF, GM-CSF, SCF, TGF-α,
RANTES (CCL5), eotaxin-1 (CCL11), and CXCL5 (86), many of
which are present in other immune secreted vesicles. In contrast
to exosomes, eosinophil granules are larger in size (500–1000 nm)
and express lysosome-associated membrane glycoproteins such
as LAMP-2 (CD107b) and LAMP-3 but vesicle-associated mem-
brane protein-2 is not expressed on human eosinophil granules
(Figure 2) (87). Despite the selective and well-controlled secre-
tion of cytokines and cationic proteins, there is no evidence that
cell-free eosinophilic granules can function as antigen-presenting
structures or express MHC class II molecules. Little is known
at present about eosinophil-derived exosomes or secreted vesi-
cles, and even less regarding their immunomodulatory functions.
The pro-inflammatory and cytotoxic properties of eosinophils
make them an interesting target for cancer immune surveillance.
Indeed, if cancer cells could inactivate eosinophils or take advan-
tage of other leukocytes recruitment that eosinophils promote,
they might have a means to elude one of the main effector cells of
the innate immune system. While the role of eosinophil-secreted
exosomes is yet to be defined, they may have an important role in
the pathogenesis of several diseased such as asthma and tumor pro-
gression. Their physiological role executing cytotoxic effects could
be likely modulated by pro-inflammatory factors. Moreover, the
release of their cargo together with mast cells could be considered
as a future biomarker of chronic pathologies characterized by an
inflammatory microenvironment.
NK CELLS
Natural killer cells are among the most powerful effectors lympho-
cytes in the immune system: 15% of all circulating lymphocytes
are NKs, and they are also found in many peripheral tissues. Dif-
ferent factors recruit NK cells to the peripheral tissues, such as
IL-12, IL-15, IL-2, IFN-α, or β, and their role in innate immu-
nity and in anti-tumor defense has been studied (88). Recent
evidence shows that NK cells isolated from the blood of healthy
donors release exosomes expressing proteins such as CD56 and
that they contain the killer protein perforin (Figure 2) (89). Exo-
somes released by NK cells may exert cytotoxic activity against
tumor target cells, pointing to an important role of NK cell-derived
exosomes in immune surveillance (Figure 3) (89). NK-derived
exosomes contain FasL, a traditional pro-apoptotic ligand (90)
that has been implied in tumor tolerance (91), and perforin, a
granzyme implicated in tumor and immune homeostasis (92),
which lead to literary name NK-derived exosomes as “nanobul-
lets” (93). The proliferation and cytotoxic activities of NK cells is
impaired by tumor-derived exosomes, both ex vivo and in vitro,
and this effect has been correlated to the growth of the tumor
(94). In fact, exosomes released by human pancreas and colon car-
cinoma cells in culture express high levels of Hsp70, and they can
stimulate NK cell activity, inducing their migration and cytolytic
activity (95). Other reports described that tumor-derived exo-
somes can also promote tumor immune evasion by impairing NK
cells effector functions in human breast cancer, mesothelioma,
and various types of blood cancers (96). NKG2D is one of the
most potent activating receptors expressed on the surface of NK
cells, and it plays an important role in activating the anti-cancer
immune response through an interaction with stress-inducible
NKG2D ligands (NKG2DL) on transformed cells (97). However,
cancer cells have developed numerous mechanisms to evade the
immune system, NKG2D ligand-bearing exosomes downregu-
late NKG2D receptor-mediated cytotoxicity in vitro (98). Current
tumor immunotherapies may produce severe side effects, although
a Cbl-b-knockout mouse and mice treated with a TAM blocker do
not exert severe signs of inflammation or autoimmunity, repre-
senting a therapeutic window for Cbl-b/TAM receptor inhibition
to mediate tumor rejection without provoking serious cytotoxicity
(99). The most recent data in this field suggest that NK cell-derived
exosomes play an active role in the regulation of immune surveil-
lance and homeostasis. Moreover, due to their cytotoxic activity,
NK-derived exosomes are probably the best example so far of
“nanobullets” that could possibly be used in future therapeutic
approaches against different pathologies, including tumors.
REINTERPRETING CANCER, LESSONS LEARNED FROM
PARASITE WORLD
When parasites infect an organism, they infiltrate its tissues and
organs, trying to avoid the host’s defense systems. Eventually, they
will find their niche, proliferate, and develop a full infection if
the immune response is insufficient. This behavior resembles the
colonization of metastatic sites by cancer cells and their adapta-
tion to the metastatic niche, suggesting that both processes may
share similar mechanisms (26). Both microorganisms and tumor
cells need to interact with the innate immune system and evade
leukocyte surveillance in order to achieve successful coloniza-
tion. A comprehensive study of the tapeworm genome identified
evolutionary adaptations that may influence such colonization,
affecting metabolism, detoxification mechanisms, loss of home-
obox genes, empowered stemness, and altered cadherins (100). As
such, some enzymes involved in these adaptations may be relevant
targets for anti-parasitic drug development and could also possi-
bly be used as anti-cancer therapies. For example, anti-parasitic
agents such as mebendazalone have been described as a treat-
ment of chemotherapy-resistant malignant melanoma (101) and
likewise, different classes of anti-malarial drugs (artemisinins, syn-
thetic peroxides, and DHFR [dihydrofolate reductase] inhibitors)
have strong anti-proliferative activity on cancer cells (102). These
observations have encouraged further research into the possible
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anti-cancer applications of new small compounds with anti-
parasitic activity. Importantly, there are cases in which parasitic
infections are the cause of cancer, expanding our perception of
the relationship between parasites and cancer (103, 104). While
such a relationship of carcinogenesis is not fully understood,
it may be related to aberrant innate immunity and chronic
inflammation.
Parasites secrete exosomes that interact with the innate and
adaptive immune systems (105). Exosomes from Leishmania dono-
vani modulate the monocyte response to IFN-γ, promoting IL-10
production and inhibiting TNF-α. L. donovani is the parasite
responsible for the most severe leishmaniasis, and it infects the
mononuclear phagocyte system, affecting macrophages in the
spleen, liver, and bone marrow via a Rac1- and Arf6-dependent
process (106). M. tuberculosis is another microbe that uses a strat-
egy that cancer cells may mimic. Virulent M. tuberculosis evades
innate immunity by inhibiting apoptosis and triggering necrosis
of host macrophages, and escaping from adaptive immunity by
delaying its initiation (107). This interaction with macrophages
might me mimicked by cancer cells. Epigenetic modulation of the
immune response has also been described in Plasmodium falci-
parum, the protozoan parasite responsible for the human malaria.
P. falciparum has 60 var genes encoding distinct antigenic forms
of the virulence protein PfEMP1 (P. falciparum erythrocyte mem-
brane protein 1). The parasite expresses only one var gene at any
time point during infection to avoid detection by the immune sys-
tem,yet the mechanism controlling the silencing of the other 59 var
genes is unknown (108). An epigenetic mechanism is thought to be
involved in this silencing, whereby the histone lysine methyltrans-
ferase PfSETvs controls, which gene will be expressed and thus,
enables the parasite to evade the immune system (108). There-
fore, the transfer of epigenetic modulators through exosomes may
participate in the avoidance of immune surveillance.
THE ROLE OF INNATE IMMUNITY IN SPECIFIC PATHOLOGIES
Activation of the innate immune system, or the inhibition of pro-
tumorigenic and inflammatory cells, can produce anti-tumoral
effects in immunosuppressed cancer patients. Here, we discuss
specific cancer types that provide evidence of the crucial role mast
cells, macrophages, and NK cells could play in tumor formation
and progression, as well as the targeted immunotherapy currently
available in such cases.
THE ROLE OF MAST CELLS AND MACROPHAGES IN
NEUROFIBROMATOSIS-1 RELATED TUMORS
Although important roles of the tumor microenvironment and
mast cells in the initiation and progression of neurofibroma have
been described (109), their interactions remain poorly under-
stood. The hypothesis that in neurofibroma, tumorigenic cells
do not grow in isolation but rather the microenvironment con-
tributes critically to their formation, suggests that exosomes may
possibly mediate this process. So far, there is a lack of informa-
tion of the role of secreted vesicles in the communication between
tumor and stromal cells in neurofibroma progression, a compli-
cation of neurofibromatosis-1 (NF1) (110). Neurofibromas are
formed in association with peripheral nerves and as well as con-
taining large collagen deposits, they are composed of Schwann
cells, fibroblasts, vascular cells, and mast cells. Tumor progression
requires complex interactions between Schwann cells and NF1 het-
erozygous (NF1+/−) cell lineages in the tumor microenvironment
including innate immune system cells (111). Exposure of NF1+/−
mast cells to conditioned media from Schwann cells and mast
cells in vitro provoked hypersensitivity (112, 113), suggesting that
activated mast cells can release inflammatory cytokines, growth
factors, and other components such as extracellular vesicles, which
may stimulate tumorigenic Schwann cell transformation and sup-
port the recruitment of macrophages, fibroblasts, and blood ves-
sels. In addition, mast cells can secrete VEGF, a potent stimulant
for Schwann cell proliferation and survival. VEGF inhibits the
differentiation and functional maturation of DCs by suppressing
NF-κB in hematopoietic stem cells, and by downregulating the
anti-tumor response (114). VEGF has been demonstrated to be
carried in tumor-shed vescicles and to be released in a bioactive
form (115). Therefore, mast cell-derived exosomes are good can-
didates to mediate tumoral transformation. Several studies have
tested the hypothesis that NF1 heterozygotes enhance angiogenesis
and may promote neurofibroma formation (116, 117); neverthe-
less, none of these studies showed so far the role of secreted
vesicles in the communication between different cell types. We
postulate that tumor-secreted exosomes could play a novel role in
cell–cell communication with mast and endothelial cells during
neurofibroma progression.
Currently, many cancer therapies targeting innate immunity
have been studied in the context of NF1 and some such trials
are still ongoing (Table 1). Some of these drugs may target not
only tumor molecules or soluble factors but also tumor-shed vesi-
cles. NF1 patients with symptomatic plexiform neurofibromas had
decreased tumor volumes in a phase 2 study after treatment with
kinase inhibitor imatinib mesylate, which targets the c-Kit recep-
tor, ABL, BCR-ABL, and PDGFRα (118). Based on the hypothesis
that mast cell secretions contribute to the growth and associated
symptoms of neurofibromas, ketotifen (a mast cell granule stabi-
lizer) was shown to reduce neurofibroma-associated symptoms
and tumor growth. A reduction in exosomes release might be
associated to the treatment with granule stabilizers. A subsequent
multiphase trial confirmed the symptomatic control with this
agent, yet without neurofibroma reduction (119). As malignancy
develops, macrophages are recruited at higher densities to periph-
eral nerves and neurofibromas in mice and human beings when
NF1 is inactivated in Schwann cells (120). PLX3397 (Plexxikon) is
a novel small molecule that selectively inhibits CSF1R, c-Kit, and
mutant FLT3 kinases, by targeting key components of both the
tumor and its microenvironment (such as macrophages, osteo-
clasts, and mast cells). The effects of PLX3397 in neurofibroma
formation indicated that macrophage infiltration seems to have
both anti- and pro-tumorigenic roles depending on the disease
stage (120). Currently, the lack of efficient treatment options for
neurofibroma patients is due to the lack of understanding the
mechanisms how it progresses. Defining if exosomes play a role
in neurofibroma-MPNST transformation will help in identifying
individuals who may be at a high risk of progression. Early diag-
nosis of malignant transformation is key to design therapeutic
approaches in NF1 patients, and exosomes could be the missing
biomarker for neurofibromatosis.
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Table 1 | Current clinical trials in cancer involving innate immunity modulation.
Agents Molecular targets Target cells
(innate immunity)
Tumor Phase Reference
Imatinib c-KIT, ABL, BCR-ABL, PDGFRA Mast cells PN NF1 2 (118)
Ketotifen fumarate Blocking of histamine binding (H1 receptor),
inhibition calcium-dependent vesicle
degranulation of activated mast cell
Mast cells Neurofibromas NF1 Controlled
multiphase
trial
(119)
PLX3397 CSF1R, KIT, FLT3-ITD Machrophages Mast cells PN NF1 (Nf1flox/flox
mouse model)
P (in vivo) (120)
L-MTP-PE, Mifamurtide
Mepact
NOD2, NLRP3 (NF-kB, MAPKs activation) Macrophages Osteosarcoma 3 (121, 122)
Haploidentical NK
cells+ IL-2+CT
Cytolytic activity NK Neuroblastoma 1 clinicaltrials.gov
(NCT00698009)
Allogeneic NK cells+
3F8+CT
Cytolytic activity NK Neuroblastoma 1 clinicaltrials.gov
(NCT00877110)
Humanized Anti-GD2
(hu14.18K322A)±NK
cells+CT
Cytolytic activity NK Neuroblastoma 1 clinicaltrials.gov
(NCT01576692)
Humanized anti-GD2
(Hu3F8)+GM-CSF
Disialoganglioside GD2+GM-CSFR NK cells, monocytes/
macrophages
Neuroblastoma 1 clinicaltrials.gov
(NCT01757626)
Rhu-GM-CSF+CT GM-CSFR Monocytes/macrophages,
CD4-T,NK, DCs
Colorectal cancer 2 (123)
Dendritic cells+PANVAC
or PANVAC+GM-CSF
Carcinoembryonic antigen and mucin-1 Tumor antigen specific
T cells
Colorectal cancer 2 (124)
PN, plexiform neurofibroma; P, preclinical; MPNST, malignant peripheral nerve sheath tumor; PVNS, pigmented villonodular synovitis; GBM, glioblastoma; TMZ,
temozolomide; RT, radiotherapy; CT, chemotherapy.
THE ROLE OF TUMOR-INFILTRATING MACROPHAGES IN
OSTEOSARCOMA
Osteosarcoma is the most common primary malignant tumor aris-
ing in the bone, and it occurs most frequently in adolescents. In
patients with osteosarcoma, the lungs are the most common site of
distant metastasis (125) and the most common site for recurrence.
The immune system is likely to play an important role in
osteosarcoma progression, and indeed, the presence of infil-
trating macrophages is associated with improved survival and
decreased incidence of metastasis. However, the role of vesicles
in the osteosarcoma/immune system interaction has not been
demonstrated yet. Thus, strategies that target innate immunity
seem to represent a promising approach to treat this tumor
(Table 1). Mifamurtide (liposomal muramyl tripeptide phos-
phatidyl ethanolamine: L-MTP-PE, Mepact), is a modulator of
innate immunity that stimulates the anti-tumoral effect of mono-
cytes and macrophages (121). The results of an US random-
ized phase III trial (INT 0133) of L-MTP-PE associated to
chemotherapy to treat osteosarcoma reported a significant inter-
action of the combination L-MTP-PE/ifosfamide (122). M1 and
M2 macrophages appear to inhibit growth of osteosarcoma cells
in vitro and, in particular, the M1 subpopulation is activated by L-
MTP-PE when associated with IFNγ and the M2 macrophages
with IL-10 in the presence of anti-EGFR cetuximab involved
in antibody-dependent phagocytosis (126). Osteosarcoma cell
secrete exosomes, and they might interact with macrophages and
other immune cells, as has been described above. We postulate a
role of exosomes as mediators of immune response in osteosar-
coma, and other studies will be needed to develop new drugs that
enhance the innate immune system in these patients.
NK CELLS IN NEUROBLASTOMA TREATMENT AND PROGRESSION
Natural killer cells recognize and eliminate transformed cells that
downregulate the expression of human leukocyte antigen (HLA)
class I molecules (127). The efficiency of NKG2D in NK cell-
mediated cytotoxicity is strictly correlated with the expression
and surface density of the MHC class I-related chain (MICA or
NKG2D ligand) on target tumor cell (128). Neuroblastoma is
a neuroendocrine tumor, arising from neural crest element of
the sympathetic nervous system and represents the most com-
mon extracranial solid cancer in childhood. Patients with neu-
roblastoma show high serum soluble MICA (sMICA)associated
with the downregulation of surface NKG2D in normal periph-
eral blood CD8+ cells, decreased NK-mediated killing of MICA+
neuroblastoma cells, HLA class I antigen-deficiency and defects in
antigen processing (129). Furthermore, neuroblastoma may evade
the immune system by downregulating activating ligands for the
immunoreceptor NKG2D expressed by cytotoxic T lymphocytes
and NK cells (130). It is reported that prostate carcinoma cell
line secrete MICA in association with exosomes, and this may
contribute to immune escape mechanism of different tumoral
cells (131). Tumor-derived exosomes can both stimulate NK cell
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activity or promote tumor immune evasion by impairing NK cells
effector (132). Neuroblastoma cell lines are known to release exo-
somes (133), and their role in immune surveillance should be
investigated, particularly as they might represent useful targets
for immunotherapeutic approaches (134). NK-derived exosomes
increase NK cytotoxic potential over the tumor. NK cells have been
successfully used in adoptive immune cell infusions to cure vari-
ous advanced or metastatic tumors inducing a graft-versus-tumor
(GVT) effect (135), so NK-derived exosomes could be used as
drugs to reduce neuroblastoma tumor size. At the moment, differ-
ent trials are ongoing to evaluate the efficacy of NK cell infusion in
patients with relapsed or refractory neuroblastoma, in conjunction
with the use of anti-GD2 antibodies (Table 1, clinicaltrials.gov).
INNATE IMMUNITY AND COLORECTAL CANCER
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer in males and the second in females. The risk of develop-
ing CRC is influenced by both environmental and genetic factors
and patients with inflammatory bowel diseases (IBDs), among
which the most common forms are Crohn’s disease and ulcera-
tive colitis, present a higher risk of developing colitis-associated
CRC (136). We postulate that the continuous secretion of exo-
somes and recruitment of stromal cells promoted by the constant
inflammation in IBD patients may be a risk factor in the develop-
ment of CRC. However, the majority of CRCs develops without
any apparent pre-existing inflammatory pathology. Commensal
microorganisms contribute to host defenses, controlling intesti-
nal inflammation,and maintaining intestinal homeostasis through
crosstalk with the innate immune system. The benefits of target-
ing innate immunity in colon cancer has been studied, although a
phase 2 study of recombinant human GM-CSF administrated pre-
operatively to colon cancer patients failed to find an association
with beneficial immune function (123). Another trial compared
the effectiveness of two different vaccines (DCs modified with
PANVAC or PANVAC plus GM-CSF) in the treatment of patients
with CRC (124) showed that DCs and poxvector vaccines have sim-
ilar activity but that the survival of vaccinated patients was longer
than for unvaccinated patients. Patients with CRC present higher
serum exosomal levels if compared with controls, but their role
in the innate immunity is not yet described (137). Exosomes (or
tolerosomes) have been shown to contribute to maintaining toler-
ance to food antigens in the gastrointestinal tract (138). Therefore,
exosomes released by immune cells not only play an immunos-
timulatory effect but they are also involved in the maintenance of
immunological tolerance, which may be lost in inflammatory dis-
eases, thereby contributing to cancer development. Furthermore,
a study showed significantly higher levels of exosomal miRNAs in
the serum of patients with colon cancer than in healthy controls,
levels that were substantially downregulated after surgical resec-
tion of the tumors (137). Inflammation and cancer progression
are very closely related in CRC progression, and exosomes are key
players in this interplay.
CONCLUSION
The immune system performs tumor immune surveillance
to inhibit tumorigenesis and prevent the establishment of a
premetastatic niche. In this context, it remains unclear which are
the effector molecules that allow cancer cells to evade immune
surveillance and that drive immunoediting and tumor promoting
inflammation through interactions in the tumor microenviron-
ment. In this sense, it would be of interest to determine how
immune activity can be harnessed for clinical benefit. There is new
evidence focusing on the interaction between the innate immune
system and effector molecules secreted by tumor cells. However, to
date, there is limited data about as to how tumor-secreted vesicles
can act as “first messengers” to prepare the metastatic niche and
how innate immunity reacts to that threat. One critical point in
this field is that the majority of the studies up to date involves nor-
mally ex vivo manipulations on extracellular vesicles that do not
necessarily reflect the physiological situation. Similarly, in most
of the studies, it is hard to determine the biological role of extra-
cellular vesicles in vivo and difficult to interpret. Furthermore,
very often the exact source of extracellular vesicles is not well
known, and the assays performed made the mechanistic analysis
difficult to interpret. There is scarce information yet regarding the
secreted vesicles actions in physiological conditions although pro-
gression rates in the field are promising. A better characterization
of the source and more mechanistic assays would be required to
define the specific role of extracellular vesicles secreted by each
cell type. Do tumor-secreted vesicles regulate the behavior of the
innate immune system during metastasis? Can they act as an invis-
ible threat to orchestrate metastatic niche formation? Can they be
stopped? Further research is needed to define the role of secreted
vesicles in metastasis and how this information “educates” the
tumor microenvironment.
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